{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:30:54Z","timestamp":1790656254705,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03577-w","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:08:40Z","timestamp":1748232520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study"],"prefix":"10.1186","volume":"27","author":[{"given":"Jae-Bum","family":"Jun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Soon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Geun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doo-Ho","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie Jin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Jae","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ah","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hee","family":"Suh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungwoo","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yoon","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hee","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Soo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"3577_CR1","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.semarthrit.2020.04.008","volume":"50","author":"JA Singh","year":"2020","unstructured":"Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50:S11\u20136.","journal-title":"Semin Arthritis Rheum"},{"key":"3577_CR2","doi-asserted-by":"publisher","first-page":"925219","DOI":"10.3389\/fphar.2022.925219","volume":"13","author":"C Jenkins","year":"2022","unstructured":"Jenkins C, Hwang JH, Kopp JB, Winkler CA, Cho SK. Review of urate-lowering therapeutics: from the past to the future. Front Pharmacol. 2022;13:925219.","journal-title":"Front Pharmacol"},{"key":"3577_CR3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.7861\/clinmedicine.17-1-54","volume":"17","author":"A Abhishek","year":"2017","unstructured":"Abhishek A, Roddy E, Doherty M. Gout - a guide for the general and acute physicians. Clin Med (Lond). 2017;17:54\u20139.","journal-title":"Clin Med (Lond)"},{"key":"3577_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2017.12.005","volume":"48","author":"P Chandratre","year":"2018","unstructured":"Chandratre P, Mallen C, Richardson J, Muller S, Hider S, Rome K, et al. Health-related quality of life in gout in primary care: baseline findings from a cohort study. Semin Arthritis Rheum. 2018;48:61\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"3577_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72:744\u201360.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3577_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","volume":"79","author":"P Richette","year":"2020","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, et al. 2018 Updated European league against rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis. 2020;79:31\u20138.","journal-title":"Ann Rheum Dis"},{"key":"3577_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nature742","volume":"417","author":"A Enomoto","year":"2002","unstructured":"Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447\u201352.","journal-title":"Nature"},{"key":"3577_CR8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","volume":"16","author":"HJ Shin","year":"2011","unstructured":"Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, et al. Interactions of urate transporter URAT1 in human kidney with uricosuric drugs. Nephrol (Carlton). 2011;16:156\u201362.","journal-title":"Nephrol (Carlton)"},{"key":"3577_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s42358-019-0080-x","volume":"59","author":"VF Azevedo","year":"2019","unstructured":"Azevedo VF, Kos IA, da Vargas-Santos AB. Rocha Castelar Pinheiro G, Dos Santos Paiva E. Benzbromarone in the treatment of gout. Adv Rheumatol. 2019;59:37.","journal-title":"Adv Rheumatol"},{"key":"3577_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/jpet.115.231647","volume":"357","author":"SO Ahn","year":"2016","unstructured":"Ahn SO, Ohtomo S, Kiyokawa J, Nakagawa T, Yamane M, Lee KJ, et al. Stronger uricosuric effects of the novel selective URAT1 inhibitor UR-1102 Lowered plasma urate in tufted capuchin monkeys to a greater extent than benzbromarone. J Pharmacol Exp Ther. 2016;357:157\u201366.","journal-title":"J Pharmacol Exp Ther"},{"key":"3577_CR11","first-page":"1976","volume":"58","author":"HA Lee","year":"2019","unstructured":"Lee HA, Yu KS, Park SI, Yoon S, Onohara M, Ahn Y, et al. URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers. Rheumatology (Oxford). 2019;58:1976\u201384.","journal-title":"Rheumatology (Oxford)"},{"key":"3577_CR12","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Y\u00fc TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20:895\u2013900.","journal-title":"Arthritis Rheum"},{"key":"3577_CR13","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","volume":"74","author":"T Neogi","year":"2015","unstructured":"Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout classification criteria: an American college of rheumatology\/european league against rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789\u201398.","journal-title":"Ann Rheum Dis"},{"key":"3577_CR14","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/14656566.2021.1918102","volume":"22","author":"T Ishikawa","year":"2021","unstructured":"Ishikawa T, Takahashi T, Taniguchi T, Hosoya T. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021;22:1397\u2013406.","journal-title":"Expert Opin Pharmacother"},{"key":"3577_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3899\/jrheum.140460","volume":"92","author":"AS Kydd","year":"2014","unstructured":"Kydd AS, Seth R, Buchbinder R, Falzon L, Edwards CJ, van der Heijde DM, et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl. 2014;92:33\u201341.","journal-title":"J Rheumatol Suppl"},{"key":"3577_CR16","doi-asserted-by":"crossref","unstructured":"Dewi C, Puspita F, Puspitasari IM, Zakiyah N. Hepatic safety of febuxostat and allopurinol for gout patients: a systematic review of randomized controlled trial. Ther Clin Risk Manag. 202319:731\u201343.","DOI":"10.2147\/TCRM.S424598"},{"key":"3577_CR17","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","volume":"56","author":"AK Tausche","year":"2017","unstructured":"Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, et al. Lesinurad monotherapy in gout patients intolerant to a Xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study. Rheumatology (Oxford). 2017;56:2170\u20138.","journal-title":"Rheumatology (Oxford)"},{"key":"3577_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/rheumatology\/key245","volume":"58","author":"R Terkeltaub","year":"2019","unstructured":"Terkeltaub R, Saag KG, Goldfarb DS, Baumgartner S, Schechter BM, Valiyil R, et al. Integrated safety studies of the urate reabsorption inhibitor lesinurad in treatment of gout. Rheumatology (Oxford). 2019;58:61\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"3577_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10157-020-01849-0","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol. 2020;24:62\u201370.","journal-title":"Clin Exp Nephrol"},{"key":"3577_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10157-020-01851-6","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24:71\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"3577_CR21","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1073\/pnas.0409500102","volume":"102","author":"SI Hung","year":"2005","unstructured":"Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102:4134\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3577_CR22","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/FPC.0b013e328330a3b8","volume":"19","author":"W Tassaneeyakul","year":"2009","unstructured":"Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics. 2009;19:704\u20139.","journal-title":"Pharmacogenet Genomics"},{"key":"3577_CR23","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3904\/kjim.2022.036","volume":"37","author":"EH Park","year":"2022","unstructured":"Park EH, Choi ST, Song JS. Current state and prospects of gout treatment in Korea. Korean J Intern Med. 2022;37:719\u201331.","journal-title":"Korean J Intern Med"},{"key":"3577_CR24","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450\u201361.","journal-title":"N Engl J Med"},{"key":"3577_CR25","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1002\/art.20935","volume":"52","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, et al. Febuxostat, a novel nonpurine selective inhibitor of Xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916\u201323.","journal-title":"Arthritis Rheum"},{"key":"3577_CR26","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13075-018-1593-0","volume":"20","author":"L Gunawardhana","year":"2018","unstructured":"Gunawardhana L, Becker MA, Whelton A, Hunt B, Castillo M, Saag K. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018;20:99.","journal-title":"Arthritis Res Ther"},{"key":"3577_CR27","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/art.24209","volume":"59","author":"HR Schumacher","year":"2008","unstructured":"Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double\u2010blind, parallel\u2010group trial. Arthritis Rheum. 2008;59:1540\u20138.","journal-title":"Arthritis Rheum"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03577-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03577-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T04:08:42Z","timestamp":1748232522000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-025-03577-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3577"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03577-w","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,26]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the relevant Institutional Review Board for each of the 18 participating centers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"113"}}